In Silico and In Vitro Approach for Evaluation of the Anti-Inflammatory and Antioxidant Potential of Mygalin
Abraham Espinoza-Culupú, Nayara Del Santos, Mariella Farfán-López, Elizabeth Mendes, Pedro Ismael da Silva Junior, Monamaris Marques Borges, Takeshi Uemura, Yusuke Terui · 2023
Read In Silico and In Vitro Approach for Evaluation of the Anti-Inflammatory and Antioxidant Potential of Mygalin by Abraham Espinoza-Culupú, Nayara Del Santos, Mariella Farfán-López, Elizabeth Mendes, Pedro Ismael da Silva Junior, Monamaris Marques Borges, Takeshi Uemura, Yusuke Terui (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10707111.txt.
Description
Abraham Espinoza-Culupú and colleagues test mygalin, a lab-made copy of the natural compound spermidine, as a possible anti-inflammatory and antioxidant drug lead. Earlier work showed it kills Escherichia coli and calms macrophages facing bacterial toxin. Computer screens first checked its safety and likely targets, and docking placed it on three inflammation enzymes, COX-2, iNOS and 5-LOX.
In cell tests, mygalin cut the toxin-driven rise of iNOS and COX-2 and lowered oxidative stress, all without harming cell survival. It also showed strong antioxidant action in a standard assay and blocked heat-driven red cell damage. The authors see mygalin as a sound candidate for deeper study as a new inflammation fighter.
Catalog record
| CREATOR | Abraham Espinoza-Culupú, Nayara Del Santos, Mariella Farfán-López, Elizabeth Mendes, Pedro Ismael da Silva Junior, Monamaris Marques Borges, Takeshi Uemura, Yusuke Terui |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |